Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.

被引：0
|
作者：
Safonov, Anton Mikhailovich
Bandlamudi, Chaitanya
Selenica, Pier
Marra, Antonio
Ferraro, Emanuela
Mandelker, Diana
Solit, David B.
Berger, Michael F.
Norton, Larry
Powell, Simon N.
Shen, Ronglai
Robson, Mark E.
Chandarlapaty, Sarat
Reis-Filho, Jorge S.
Razavi, Pedram
机构：
[1] Hosp Univ Penn, Philadelphia, PA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Milan, Italy
[4] Sloan Kettering Inst, Weill Cornell Med Coll, Kravis Ctr Mol Oncol, Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1010
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
    Portman, Neil
    Alexandrou, Sarah
    Carson, Emma
    Wang, Shudong
    Lim, Elgene
    Caldon, C. Elizabeth
    ENDOCRINE-RELATED CANCER, 2019, 26 (01) : R15 - R30
  • [22] Clinical development of CDK4/6 inhibitor for breast cancer
    Iwata, Hiroji
    BREAST CANCER, 2018, 25 (04) : 402 - 406
  • [23] Clinical development of CDK4/6 inhibitor for breast cancer
    Hiroji Iwata
    Breast Cancer, 2018, 25 : 402 - 406
  • [24] Cdk4/6 kinase inhibitor resistance in prostate cancer
    De Leeuw, Renee
    Schiewer, Matthew J.
    McNair, Christopher
    Augello, Michael A.
    Yoshida, Akihiro
    Hazard, Edward S.
    Courtney, Sean
    Hardiman, Gerard T.
    Drake, Justin
    Feng, Felix Y.
    Tomlins, Scott
    Hussain, Maha H.
    Diehl, J. Alan
    Kelly, William K.
    Knudsen, Karen E.
    CANCER RESEARCH, 2017, 77
  • [25] TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
    Cordani, Nicoletta
    Mologni, Luca
    Piazza, Rocco
    Tettamanti, Pietro
    Cogliati, Viola
    Mauri, Mario
    Villa, Matteo
    Malighetti, Federica
    Di Bella, Camillo
    Jaconi, Marta
    Cerrito, Maria Grazia
    Cavaletti, Guido
    Lavitrano, Marialuisa
    Cazzaniga, Marina Elena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (22)
  • [26] Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy
    Moukas, Stefanos Ioannis
    Dohn, Merle
    Lehnerdt, Catrin
    Welt, Anja
    Kolberg, Hans-Christian
    Hoffmann, Oliver
    Kimmig, Rainer
    Kasimir-Bauer, Sabine
    Keup, Corinna
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [27] Bypass kinase pathways lead to acquired CDK4/6 inhibitor resistance in prostate cancer.
    de Leeuw, Renee
    McNair, Christopher M.
    Schiewer, Matthew J.
    Neupane, Neermala P.
    Augello, Michael A.
    Li, Zhen
    Cheng, Larry
    Yoshida, Akihiro
    Diehl, J. Alan
    Hazard, E. Starr
    McCourtney, Sean M.
    Hardiman, Gary
    Hussain, Maha H.
    Drake, Justin M.
    Kelly, Wm. Kevin
    Knudsen, Karen E.
    CANCER RESEARCH, 2018, 78 (16) : 47 - 47
  • [28] CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety
    Wekking, Demi
    Lambertini, Matteo
    Dessi, Mariele
    Denaro, Nerina
    Bardanzellu, Fabio
    Garrone, Ornella
    Scartozzi, Mario
    Solinas, Cinzia
    SEMINARS IN ONCOLOGY, 2023, 50 (06) : 131 - 139
  • [29] CDK4/6 inhibitor combination therapy for the treatment of RB1-intact HCC
    Sheng, Jindan
    Kohno, Susumu
    Takahashi, Chiaki
    CANCER SCIENCE, 2022, 113 : 555 - 555
  • [30] HPV E7 oncogene expression impairs Rb function and confers CDK4/6 inhibitor resistance in cervical cancer.
    Xiong, Yudi
    Wang, Yuan
    Ou, Haibin
    Zhou, Yunfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17504 - E17504
12345